Comparison of 20-core Versus 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer

This study has been completed.
Sponsor:
Information provided by:
Poitiers University Hospital
ClinicalTrials.gov Identifier:
NCT00992615
First received: October 8, 2009
Last updated: August 28, 2012
Last verified: November 2009
  Purpose

The optimal number of prostate cores extracted during a prostate biopsy performed because of a suspected prostate cancer is still debated. The present consensus is to sample 12 cores. However, recent data published in the literature brought arguments in favour of a higher number, probably 20. This would have the advantages of decreasing the false negatives and the re-biopsy rate.


Condition Intervention
Prostate Cancer
Procedure: prostate biopsy

Study Type: Interventional
Official Title: Comparison of 20-core vs 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Poitiers University Hospital:

Arms Assigned Interventions
Experimental: Arm 20 cores Procedure: prostate biopsy
prostate cores - 12 or 20
Active Comparator: arm 12 cores Procedure: prostate biopsy
prostate cores - 12 or 20

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Criteria

Inclusion Criteria:

  • Patients older than 18
  • Patients with a PSA value between 3 et 20 ng/ml
  • Obtained informed consent
  • Patients able to comply with the study protocol
  • Patients covered by a social insurance

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00992615

Locations
France
service d'Urologie - CHU de Poitiers - 2 rue de la Milétrie
Poitiers, France, 86021
Sponsors and Collaborators
Poitiers University Hospital
  More Information

No publications provided by Poitiers University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00992615     History of Changes
Other Study ID Numbers: BP20-12
Study First Received: October 8, 2009
Last Updated: August 28, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on April 17, 2014